Skip to main content

Table 3 A: C-index analysis of with and without the addition of BSI to blood based biomarkers at baseline. B: C-index analysis of change in BSI and PSA at treatment follow-up

From: Automated Bone Scan Index as a quantitative imaging biomarker in metastatic castration-resistant prostate cancer patients being treated with enzalutamide

  C-index Confidence interval SE
A. Baseline analysisa (dead/total = 56/80)    
 BSI 0.71 0.64–0.77 0.03
 PSA 0.65 0.57–0.72 0.03
 ALP 0.67 0.58–0.75 0.03
 HgB 0.26 0.20–0.32 0.03
 PSA + ALP + HgB 0.67 0.58–0.74 0.03
 PSA + ALP + HgB + BSI 0.72 0.64–0.78 0.03
B. Change (∆) at week 12 (dead/total = 40/62)    
 ∆ BSI 0.75 0.68–0.81 0.05
 ∆ PSA 0.73 0.66–0.78 0.05
 ∆ PSA + ∆ BSI 0.77 0.71–0.82 0.05
  1. aBSI, PSA, ALP, and HgB values were observed skewed and therefore logarithmically transformed